A new WalletHub report ranks the happiest cities in America for 2026, plus surprising trends in sleep, mental health, quality of life and more. https://t.co/rIIddsMAx8 (Photo: Getty Images) https://t.co/OVmcHWufEJ ...

Are you a permenopausal woman or are you supporting someone who is permenopause? It might be a new word for you. But I am sure that you have met some one of us or maybe you are one of us. You just don't know it yet. Permenopause is the first part and the beginning of the menopause transition leading up to menopause, which is a woman's last bleeding. It lasts for several years and may start in your mid4s, for some earlier, others later. When the ovaries reduce their activity, the hormonal levels drop and can ...

It was many years back one summer. It was very very hot summer the March. I was having a long journey of 9 months. I really enjoyed this 9 months journey.Then suddenly that day I felt little cool. Why. Because there was a heavy rain one day before in the west coast of India.There was a lot of wind was coming and I was really enjoying. Then suddenly there was a push that I came out in this world. That was the day I was born and then I went to many many roller coaster in the life.One instant I know very sure ...

A new WalletHub report ranks the happiest cities in America for 2026, plus surprising trends in sleep, mental health, quality of life and more. https://t.co/rIIddsMAx8 (Photo: Getty Images) https://t.co/c3daEsiiCc ...

For many Indians living standards have become visibly better over the past decade. But there is a difference between the standard of living and quality of life https://t.co/x9dAF2R5Rb ...

For many Indians living standards have become visibly better over the past decade. But there is a difference between the standard of living and quality of life https://t.co/1fNZPE2WSoIllustration: Lan Truong https://t.co/njCtvKRxgS ...

So, it was two weeks before my 40th birthday and party planning was in full swing. 40 felt like a milestone and I really wanted to celebrate. Instead, I got a stage three breast cancer diagnosis.Not exactly the gift I was hoping for. I still remember meeting my oncologist, Dr. . Mark Clemens, for the first time.He was an older British gentleman. He walked into the room, sat down on one of those little wheelie stools, wheeled right up to me, and the first thing out of his mouth was, "It's okay to cry now." I ...

بسم الله الرحمن الرحیم حضار محترم دیگه با این صرف وقت پ ۶ ساعته احتمالاً خیلی خسته شده باشن ولی من سعی می‌کنم که خیلی کوتاه همین پروژه‌ای که دادن نکاتی رو تقدیمتون کنم. گرچه به من تأکید کرده بودن که دیسیپلین بحث تدکس اینه که نه کاغذ داشته باشی دیدم آقای دکتر کاغذ داره گفتن که پاورپوینتم نباید داشته باشین گفتیم خب بدون سلاح بیایم اینجا رو سن چی بگیم خلاصه همش از حافظه استفاده کنیم به هر صورت یه عنوانی رو که برگزار کنندگان ان این محفل گرم و صمیمی تعیین کرده بودن که من پیرامونش صحبت کنم موضوع شهرسازی بود و توس ...

When will life matter. When will life matter far more than profits. When will be the right time we begin to mainstream the health and life of humanity over making gains at the expense of human life.Over 70 years ago in community crude oil was first struck in commercial quantity. This liquid black gold the people of the Niger Delta were made to believe was going to transform their lives, their livelihoods and make the Niger Delta region just like one of the most advanced cities or regions of the world 70 yea ...

Immuneering Conference Call Summary Company Overview - **Company**: Immuneering - **Focus**: Development of atebumetanib for treating first-line pancreatic cancer Key Industry Insights - **Industry**: Oncology, specifically pancreatic cancer treatment - **Current Treatment Landscape**: Standard of care includes gemcitabine plus nab-paclitaxel (GNP), with overall survival rates significantly lower than those reported for atebumetanib Core Points and Arguments 1. **Overall Survival Data**: - 12-month overall survival rate for patients treated with atebumetanib plus chemotherapy is 64% [7][21] - Historical benchmark for standard of care (GNP) is approximately 35%, indicating a 29-point absolute separation [8][21] - Median overall survival for standard of care is about 8.5 months, while median for atebumetanib has not yet been reached [8][11] 2. **Quality of Life Improvements**: - Significant improvements in quality of life reported, with specific case studies highlighting patients regaining independence and experiencing less severe side effects [5][18] - Functional Assessment of Anorexia Cachexia Therapy (FAACT) score improved from 96 to 141 in a patient case study [18] 3. **Safety and Tolerability**: - Favorable safety profile with few severe side effects; only anemia and neutropenia occurred in over 10% of patients [10] - No harsh side effects observed with atebumetanib monotherapy, differentiating it from traditional chemotherapy [10] 4. **Clinical Trial Plans**: - Upcoming pivotal phase 3 trial (MapKeeper 301) will enroll approximately 510 patients, comparing atebumetanib plus modified gemcitabine nab-paclitaxel against standard GNP [20] - Primary endpoint will be overall survival, with dosing expected to begin mid-year [20] 5. **Expanded Cohort Data**: - An expanded cohort of over 50 patients is being reported, with overall survival trending consistently with the original cohort of 34 patients [12][49] - The expanded cohort includes additional patients who started treatment later, but results remain robust [49] 6. **Market Positioning**: - Immuneering aims to position atebumetanib as a best-in-class treatment for pancreatic cancer, with the potential to become the new standard of care [52] - The company emphasizes the importance of both quality and quantity of life for patients, aiming to provide effective treatment without debilitating side effects [34][52] Additional Important Content - **Patient Demographics**: The trial population is older, with a median age of 69, which reinforces the significance of the survival benefits observed [12] - **Future Milestones**: Upcoming milestones include sharing circulating tumor DNA analyses and updated survival data, as well as the initiation of phase 2 combination studies in lung cancer [21][22] This summary encapsulates the key points discussed during the Immuneering conference call, highlighting the promising data surrounding atebumetanib and its potential impact on the treatment of pancreatic cancer.